Wendell David Associates Inc. Lowers Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Wendell David Associates Inc. cut its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 10.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,068 shares of the company’s stock after selling 1,245 shares during the period. Wendell David Associates Inc.’s holdings in IDEXX Laboratories were worth $6,219,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the business. SHP Wealth Management purchased a new position in IDEXX Laboratories in the 4th quarter valued at approximately $26,000. Virtus Advisers LLC acquired a new position in shares of IDEXX Laboratories in the third quarter worth $26,000. Park Place Capital Corp purchased a new stake in shares of IDEXX Laboratories during the fourth quarter worth $29,000. Mowery & Schoenfeld Wealth Management LLC increased its position in shares of IDEXX Laboratories by 58.8% during the fourth quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock worth $37,000 after acquiring an additional 20 shares during the period. Finally, Wormser Freres Gestion raised its stake in shares of IDEXX Laboratories by 671.4% in the fourth quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock valued at $37,000 after acquiring an additional 47 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on IDXX shares. Stifel Nicolaus decreased their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. UBS Group cut their price target on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Wall Street Zen upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, June 13th. Weiss Ratings upgraded IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, June 25th. Finally, Citigroup began coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective for the company. Seven analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $751.00.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock opened at $526.44 on Wednesday. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. The company has a fifty day simple moving average of $556.85 and a 200-day simple moving average of $611.74. The stock has a market cap of $41.53 billion, a P/E ratio of 38.77, a price-to-earnings-growth ratio of 2.93 and a beta of 1.55. IDEXX Laboratories, Inc. has a 12-month low of $506.91 and a 12-month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, beating the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same quarter in the prior year, the company posted $2.91 earnings per share. IDEXX Laboratories’s revenue for the quarter was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities analysts expect that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.